Initial trials of small molecule HDAC inhibitors (HDACi) such as suberoylanilide hydroxamic acid (SAHA) and Trichostatin A have been neuroprotective in models of neurodegenerative disease [26,27]. Here, HDAC9 is linked to neurodegenerative disease.